CHINT
1.6.2022 11:26:08 CEST | Business Wire | Press release
Hannover Messe in Germany, the global industrial technology "wind vane", was held from May 30 to June 2. CHINT, the world's leading provider of smart energy solutions, presented 10 products and solutions, which covered new energy, green and environmentally friendly smart transformers, and smart buildings, at the Energy Solutions Pavilion (H11.C30).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005678/en/
Centered around new energy and the entire industry chain, CHINT shared its practices and exploration in the fields of "green energy", "smart grid”, "load reduction" and “new energy storage”. “CHINT is about green development and the forefront of carbon emission reduction in the electricity and energy sector. After all these years, CHINT has accumulated and established a great number of top clients and a rich set of user scenarios to rapidly perceive and capture changes and new demands in markets and clients,” said Lily Zhang, CEO of CHINT Electrics.
In 2021, CHINT and BYD's energy storage project orders were successfully delivered, and these two partners joined together to serve the new energy market in the UK. During that year, CHINT's Saudi Arabia smart meter project delivered more than 500,000 smart circuit breakers to local areas. CHINT Cambodia developed off-grid photovoltaic systems in local areas, providing electricity to local areas using thousands of off-grid photovoltaic installations.
CHINT’s solutions are aimed at energy transformation to help bring about global climate objectives. At the exhibition, CHINT’s exhibit featured 8 events delivered in online/offline mode, sharing CHINT's new products and solutions. CHINT shared photovoltaic solutions by having their European team put on a show for the audience so they could experience CHINT’s new energy solutions and photovoltaic applications across large-scale ground, industrial, commercial and residential fields. This showcased the attraction of the innovative "photovoltaic +" model. CHINT also shared its CHINT Smart City energy-saving, low-carbon, interconnected and efficient solutions to the audience. Meanwhile, CHINT’s smart terminal molded case circuit breakers, Arc Fault Detection Devices (AFDD), and a number of new products took center stage, showcasing the company’s strengths in smart manufacturing.
Lily Zhang believes that “through a trade exhibition platform as important as Hannover, clients from more than 140 different nations and regions around the world have joined with CHINT to engage in discussions and exchanges. The cooperation formed between CHINT and international partners is full of endless potential and will leverage the CHINT’s global solution to boost green energy development.”
ABOUT CHINT GLOBAL
CHINT Global is committed to serving as the world's leading provider of intelligent energy solutions for the whole industrial chain. After more than 2 decades of global expansion, our business and marketing network covers over 140 countries and regions worldwide, with a wide range of industries in low voltage electric, smart electrics, energy instruments and meters, green energy, etc.
As the localization progresses steadily, through business integration and industrial upgrade, CHINT Global will further open up the supply chain, optimize the service system, and establish an ecological mechanism, in order to provide innovative integrated technological service for the global energy market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005678/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom